Value Up29 targets operating income of JPY 25B by 2029. H1 results show two industrial segments outperforming plan. Annual dividend raised to JPY 51

Summary

For H1 FY2026/12, revenue came in at JPY 43,281M (+3.8% YoY) with operating income of JPY 7,689M (▲16.5%). While OEM declines in the Photo-Related business and rising raw material costs weighed on profitability, Surveillance & FA grew +29.0% and Mobility & Healthcare surged +39.6% YoY, significantly exceeding plan. H1 operating income landed virtually on plan at JPY 7,700M. Full-year revenue guidance was revised upward to JPY 93B, while operating income of JPY 18.5B was maintained from initial guidance. In H2, the company expects a Photo-Related recovery driven by 8+ new product launches and normalization of China channel inventory. The next medium-term management plan, Value Up29, announced in June, targets operating income of JPY 25B+ and sustained ROE of 20%+ by 2029, alongside a dividend payout ratio increase to 60% and approximately JPY 18B in additional shareholder returns.

Key Points (Earnings Highlights and Growth Actions)

• Management Strategy and Market View
  • Refreshed long-term vision quantitative targets: revenue of JPY 200B+ by 2035, including JPY 20B+ from new businesses. The prior target was a JPY 100B revenue company.
  • Explicitly declared a transformation from a lens-only manufacturer to a comprehensive optical and sensing solutions provider, shifting toward system/service delivery that integrates optical technology with sensing, AI, and image processing.
  • Photo-Related business is being positioned as a cash cow at CAGR 5%+, while industrial businesses target CAGR 15%+, raising non-photo revenue mix to 35%+ by 2029 and 50%+ by 2035.
  • Automotive is recognized as a challenging area for margin maintenance due to cost-down pressure from OEMs and rising Chinese competition; Surveillance & FA is concentrating resources on the mid-to-high-end segment, targeting OPM of 15%+.
• Current Business Progress and Drivers
  • The largest drag on H1 operating income was a JPY 1,560M gross margin deterioration from product mix effects, which could not be fully offset by a JPY 1,030M positive FX impact.
  • Photo own-brand sales in China declined ▲43%, but the Americas (+64%), Europe (+23%), and Japan (+6%) drove overall own-brand revenue growth of +4.2%.
  • Photo OEM continued to struggle with weak sell-through of contracted models, with H1 revenue of JPY 10.4B (▲23.2%), reflecting overall market weakness and Chinese manufacturers' rising presence (estimated ~15% domestic share in China, mainly in prime lenses).
  • Mobility & Healthcare posted automotive revenue of JPY 6.5B (+34.1%) and medical revenue of JPY 900M (+113.5%), with OPM improving +1.4pt to 24.7%.
• Strategic Initiatives and Inflection Points
  • Annual dividend revised upward from JPY 37 to JPY 51, with the 60% payout ratio applied on an accelerated basis from 2026. Interim dividend doubled YoY to JPY 20.
  • From 2027 onward, the payout floor will be the higher of 60% payout ratio or 8% DOE, with approximately JPY 18B in additional shareholder returns through the end of the next mid-term plan period.
  • A strategic investment envelope of JPY 21B has been established, with a dedicated team and hurdle rates set above cost of capital to ensure investment discipline.
  • A new business development organization has been launched to commercialize 20+ technology themes generated during the current mid-term plan.
  • On July 30, the company disclosed receipt of a non-binding proposal from Sony regarding full subsidiary acquisition; a special committee has been established and is under review.

Outlook and Strategy

• Full-year revenue guidance revised upward to JPY 93B (+9.3% YoY, +JPY 2B vs. initial plan), while operating income of JPY 18.5B and net income of JPY 13,690M are maintained from initial guidance. H2 FX assumptions are USD/JPY 160 and EUR/JPY 180.
• Photo-Related H2 recovery levers include accelerated new product launches (8+ models in H2 vs. 2 in H1) and clearing China channel inventory. Inventory of key models is expected to normalize by end-September.
• A US tariff refund is expected in Q3, providing a tailwind for H2 margin improvement.
• The next mid-term plan Value Up29 (2027–2029) outlines total cash-in of JPY 120B, comprising operating CF of JPY 89B (pre-R&D), cash on hand of JPY 16B, and debt of JPY 15B. Allocation includes R&D JPY 30B, capex JPY 20B, strategic investments JPY 21B, dividends JPY 31B, and additional shareholder returns JPY 18B.
• In new domains, the company is advancing development of a SWIR non-contact soil analysis device with investee Mapry, leveraging mid-infrared laser technology from LighTouch Technology, joint research with Osaka University on chip-type near-infrared light sources, and laser processing heads/beam profilers.
• Equity ratio to be brought down from 81% in 2025 to approximately 75% by 2029, maintaining liquidity at roughly 3 months of revenue, with a commitment to sustained ROE of 20%+.

Positive Factors

• Combined H1 revenue from the two industrial segments reached JPY 15,746M, exceeding plan by JPY 2,746M (our estimate).
• Surveillance & FA outperformed plan across all categories, with revenue 1.2x plan and operating income approximately 1.5x plan. Surveillance lens revenue was JPY 4.2B (+33.6% YoY), driven by developed-market demand.
• FA returned to growth at approximately 1.4x revenue as customer-side inventory adjustments ran their course, with clear recovery by region—Europe +40%, China +55%.
• Mobility & Healthcare full-year guidance revised upward to revenue JPY 15.5B and operating income JPY 3.5B, with OPM of 22.6%, exceeding the company-wide average.
• As an independent player, the company's key advantage is the ability to offer own-brand lenses compatible with lens mounts of multiple camera manufacturers. By leveraging a single optical design across multiple mounts, the company significantly reduces manufacturing costs and achieves high margins.
• Q2 revenue of JPY 24.8B marked a V-shaped recovery from Q1's JPY 18.5B, rising +11.4% YoY and restoring momentum.

Concerns

• H1 gross margin was 41.9%, down ▲3.4pt YoY, as rising raw material, utility, and logistics costs could not be fully absorbed by cost reduction efforts.
• Photo-Related full-year operating income guidance revised down JPY 1.1B from initial plan to JPY 16.1B, reflecting higher component costs, shipping expenses, and increases in personnel/R&D spending.
• Photo OEM volume is difficult to control, making it a source of quarterly earnings volatility; portfolio diversification through new customer acquisition remains a challenge.
• Automotive is recognized as a challenging area for maintaining current margins due to cost-down demands from automakers and intensifying competition from Chinese players.
• Surveillance & FA camera module segment faces a parts supply shortage, with full-year revenue now projected at JPY 2.1B (▲22.2% vs. initial plan). H2 margins expected to decline as R&D spending increases and SG&A is back-loaded.
• H2 FX sensitivity: JPY 1 appreciation per USD impacts operating income by ▲JPY 40M, and JPY 1 per EUR by ▲JPY 30M—reflecting continued dependence on a weak-yen assumption.
• Response to Sony's full subsidiary acquisition proposal remains under review, with both conclusion and timing uncertain.

Performance Highlights

In H1 FY2026/12, revenue reached JPY 43,281M (+3.8% YoY, +4.5% vs. plan), securing top-line growth, while operating income declined to JPY 7,689M (▲16.5% YoY). The primary drivers were OEM revenue declines and product mix deterioration in the Photo-Related business; against the H1 plan of JPY 7,700M, the result came in at ▲0.1%, virtually on plan. Recurring profit of JPY 7,741M (▲16.5% YoY) and net income of JPY 6,197M (▲9.9% YoY) both exceeded plan.

Segment Performance (H1 FY2026)

• Gross Profit Margin: 41.9% (▲3.4pt YoY)
• SG&A: JPY 10,441M (+7.5% YoY)
• Photo Own-Brand Revenue: JPY 17.1B (+4.2% YoY) / Volume: 220K units (▲2.3%)
• Photo OEM Revenue: JPY 10.4B (▲23.2% YoY) / Volume: 290K units (▲32.0%)
• Surveillance & FA Volume: 830K units (+41.7% YoY)
• H1 FX Impact: Revenue +JPY 2.48B, Operating Income +JPY 1.03B
• Inventories: JPY 17,725M, Inventory Turnover: 2.5 months (2.2 months as of June 2025)
• Operating CF: JPY 5,888M, Free CF: JPY 2,686M
• Full-Year Dividend Forecast: JPY 51 (raised from JPY 37 at initial guidance, payout ratio 60.1%)

Q&A List

• Q: Regarding the disclosure on July 30 about the receipt of Sony's full subsidiary acquisition proposal—how does Tamron view the potential synergies with Sony? Given that the company also conducts OEM for other manufacturers and has mentioned expansion to other companies, there appear to be both advantages and disadvantages. Could you share your thinking on this proposal and any forward-looking comments?
  A: We are carefully conducting information sharing and discussions between both companies in order for Tamron to assess and verify whether this proposal would enhance corporate value, and these discussions have been ongoing since receipt of the proposal. We ask for your understanding that we cannot comment further at this time.
• Q: Regarding the profit composition of the next mid-term plan, do you have a specific breakdown of the JPY 25B+ operating income target across Photo, Surveillance & FA, and Mobility & Healthcare?
  A: While we have various business areas including Photo, Surveillance & FA, and Mobility & Healthcare, specific figures for each still need to be built up going forward. That said, what we can say at this point is that we intend to maintain and improve OPM in Surveillance & FA to 15% or above. Accordingly, we expect the Surveillance & FA share to increase somewhat.
• Q: Looking at slide 7, Surveillance shows rising margins and revenue, while Automotive shows declining margins and revenue growth. What drives the difference between these two businesses? Even though pricing pressure may be stronger in automotive, unit volumes should be growing, and the near-term trend is strong. Could you elaborate on your thinking here?
  A: In automotive, OEM cost-down demands are very strong, and we expect significant pressure going forward. At the same time, Chinese competitors have been gaining strength, and competing with them makes it difficult to maintain current margins. On the other hand, in Surveillance and FA, we are focusing on the mid-to-high-end segment and concentrating resources there to improve profitability. Our strengths include our ability to address customer needs and our quality advantages in durability across various environments. Additionally, there is growing discussion around AI—particularly physical AI—which we expect to grow dramatically. AI always needs eyes and input, and in our case, that means stable capture of image data, which is where our optical performance and technology come into play. Furthermore, in Surveillance & FA, we can differentiate from Chinese competitors by selling modularized products rather than standalone lenses.
• Q: Photo OEM weakness has continued, but it appears to be gradually improving. With model transitions occurring around Q2 and Q3, should we expect a solid recovery as models turn over? Or is there a structural weakness behind OEM softness?
  A: Volume control in OEM is inherently difficult. From a medium-to-long-term perspective, given our positioning, we believe the pool of potential OEM clients remains limited, and our position in the market is quite unique. That said, there are other camera manufacturers as well, and while our relationships are currently relatively concentrated, we believe there is room for expansion. The backdrop is that camera manufacturers, expecting limited long-term growth in their photo businesses, are increasingly willing to outsource lens manufacturing via OEM as they pivot toward new domains. In this context, we believe OEM opportunities will continue to emerge and can be grown over the medium term. In the short term, we believe recovery is achievable through model transitions.
• Q: Photo OEM has been tracking below initial expectations—is this decline driven by sell-through at OEM clients or by end-market conditions? Could you also comment on whether OEM is expected to recover in H2 and beyond?
  A: The OEM weakness is fundamentally due to market softness overall, and in particular the continued weak sell-through of models we have been contracted for. Competition for market share among camera manufacturers has intensified, and Chinese lenses—primarily in prime lenses—have reached a notably high share of approximately 15%. Therefore, in the short term, volumes for our contracted models face a very challenging environment, driven both by overall market conditions and the rise of Chinese manufacturers.
• Q: OEM clients are fairly limited, which is in a sense Tamron's strength, but the P&L impact from OEM volume swings is significant on a quarterly basis. As you grow the business going forward, are you considering any contractual approaches or initiatives to achieve more stable customer relationships?
  A: We believe what is needed is a portfolio diversification approach—winning new camera manufacturer OEM contracts so that if volumes from one client fall short, new clients can provide an offset.
• Q: A timely disclosure has been made regarding the Sony acquisition. The long-term vision framework has been laid out, and the JPY 100B revenue target seems well within reach. Following the growth strategy, Tamron has its own brand and has developed proprietary capabilities, which are core strengths. If the company were to choose to come under Sony's umbrella for corporate value enhancement, wouldn't there be a risk of actually diminishing Tamron's corporate value and potential? Could President Sakuraba share his current thinking?
  A: As I explained earlier, we would like to refrain from commenting further on this matter.
• Q: Regarding current results and the H2 outlook—H1 Photo-Related revenue, including OEM, seems to be recovering somewhat, which is reassuring, but margins appear to have declined. H2 is expected to see a full recovery, but could you explain what is driving the apparent margin decline and how recovery will unfold in H2?
  A: In H2, new product launches will accelerate—from 2 new models in H1 to 8 in H2. As for China, while market softness has persisted since H2 of last year, channel inventory of key models is being worked through, and we expect levels to return to normal by end-September. Accordingly, on a global basis, volumes should increase substantially compared to H1. Additionally, a tariff refund of a certain amount is expected in Q3, which will further contribute to margin improvement. Comparing H1 to H2, we believe a significant earnings recovery is achievable.

Q&A List

• Q: As a factual matter, the securities report suggests that Sony does business with Tamron across all three categories. Photo-Related is obvious, but could you elaborate on what kind of work has been done with Sony in Surveillance & FA and Mobility & Healthcare?
  A: As a matter of principle, we refrain from commenting on specific business partners. However, for example, Sony's image sensors hold a very high global market share, and naturally our business also uses those sensors—so we can say that a relationship exists in that context. Beyond that, we would like to refrain from commenting further.
• Q: Tamron has operated as an independent third-party manufacturer. Are there things that can only be done as an independent, or value that is uniquely created by being independent? Could you share your perspective?
  A: As an independent company, we can produce lenses for multiple manufacturers under our own brand. One of our key strengths is that we design a single optical system and then deploy it across different mounts using common components. This drives down costs and improves margins, while also significantly shortening development cycles. Currently, we are committed to launching 10+ models per year—whereas not long ago the pace was around 4—representing a dramatic increase. We are achieving this with roughly the same headcount. This is one of the core advantages of being an independent player.